Background: ␤-blockade controls the ventricular response to exercise in chronic atrial fibrillation (AF), but the effects of ␤-blockers on exercise capacity in AF have been debated. Methods: Twelve men with AF (65 ؎ 8 years) participated in a randomized, double-blind, placebo-controlled study of betaxolol (20 mg daily). Patients underwent maximal exercise testing with ventilatory gas exchange analysis, and a separate, submaximal test (50% of maximum) during which cardiac output was measured by a CO 2 rebreathing technique. Results: After betaxolol therapy, heart rate was reduced both at rest (92 ؎ 27 vs 62 ؎ 12 beats/min; p < 0.001) and at peak exercise (173 ؎ 22 vs 116 ؎ 24 beats/min; p < 0.001). Maximal oxygen uptake (V O 2 ) was reduced by 19% after betaxolol (21.8 ؎ 5.3 with placebo vs 17.6 ؎ 5.1 mL/kg/min with betaxolol; p < 0.05), with similar reductions observed for maximal exercise time, minute ventilation, and CO 2 production. V O 2 was reduced by a similar extent (19%) at the ventilatory threshold. Submaximal cardiac output was reduced by 15% during betaxolol therapy (12.9 ؎ 2.3 vs 10.9 ؎ 1.3 L/min; p < 0.05), and stroke volume was higher (88.0 ؎ 21 vs 105.6 ؎ 19 mL/beat; p < 0.05). Conclusion: Betaxolol therapy in patients with AF effectively controlled the ventricular rate at rest and during exercise, but also caused considerable reductions in maximal V O 2 and cardiac output during exercise. The observed increase in stroke volume could not adequately compensate for reduced heart rate to maintain V O 2 during exercise.
C
hronic atrial fibrillation (AF) is usually characterized by a rapid, irregular ventricular response at rest and during exercise, and can be associated with reduced exercise capacity, fatigue, and a higher risk for thromboembolic events. 1, 2 Conventional pharmacologic therapy for chronic AF attempts to balance control of the rapid, irregular ventricular rate with the negative inotropic effects of most interventions. For example, ␤-blockade has been shown to be effective in reducing the ventricular rate at rest and during exercise; reductions in maximal heart rate have been demonstrated in the order of 25 to 40 beats/min. [3] [4] [5] [6] [7] [8] [9] Control of the ventricular response is generally thought to make the heart more efficient by increasing ventricular filling time, and therefore end-diastolic volume, leading to an increase in stroke volume. On the other hand, adequate ventricular control by ␤-blockade has resulted in reductions in exercise capacity; peak oxygen uptake (V o 2 ) or exercise time has been reduced by 15 to 20% in some studies, 4, 7 although ␤-blockade has had minimal effects on exercise capacity in others. 6, 9 Because heart rate is a major determinant of cardiac output, the attenuation of exercise capacity by ␤-blockade is presumably caused by reductions in cardiac output, but the extent to which cardiac output is reduced during exercise after ␤-blockade therapy in these patients has not been documented. The conflicting data on the effects of ␤-blockade on exercise capacity in AF may be due to differences in the extent to which cardiac output was reduced. In this study we performed a randomized, crossover evaluation of the effects of betaxolol (a recently approved ␤-receptor antagonist) on exercise capacity in patients with chronic AF. To evaluate the influence of ␤-blockade therapy on stroke volume and cardiac output, a subgroup of patients underwent submaximal exercise testing while these variables were measured using CO 2 rebreathing techniques.
Materials and Methods
Twelve men (mean age, 65 Ϯ 8 years) with chronic AF of at least 1 year's duration participated in the study. Clinical characteristics of the subjects are listed in Table 1 . Acutely ill patients were excluded, as were those with congestive heart failure, angina, inability to walk on a treadmill, symptomatic lung disease, or thyroid dysfunction. Patients remained on their normal therapeutic doses of digoxin. All rights and privileges were honored in accordance with a protocol approved by the Human Subjects Investigational Review Board at Stanford University, and written informed consent was obtained.
Study Protocol
Each patient underwent a randomized, double-blind, placebocontrolled crossover protocol, with a minimum washout period of 1 week between treatments. Patients received either 20 mg of betaxolol once daily or placebo. Betaxolol is a cardioselective ␤-receptor antagonist with no partial sympathomimetic activity, and a relatively long half life (16 to 22 h). Twenty mg of betaxolol represents a medium-range dose based on recent clinical studies. 8, 10, 11 Exercise Testing Subjects were asked to abstain from food, coffee, and cigarettes for at least 3 h prior to testing. Initially, all subjects received a complete history and physical examination, followed by a maximal exercise test using a manually incremented treadmill protocol. The purpose of this test was to habituate subjects to the procedure and gas exchange apparatus, establish clinical stability, and determine maximal V o 2 . On study days, an individualized ramp treadmill test was performed. 12 Changes in speed and grade of the treadmill were individualized (based on a given subject's exercise capacity on the baseline test) to yield a test duration of approximately 10 min. A standard 12-lead ECG and manual BP were obtained throughout the exercise test and recovery period. The number of QRS complexes multiplied by 10 in a 6-s rhythm strip was used to determine heart rate. 13 Exercise was continued until volitional fatigue, and the Borg 6 -20 scale 14 was used to quantify subjective effort.
Gas Exchange
Respiratory gas exchange variables were acquired continuously during exercise using the CS-100 System (Schiller America; Tustin, CA). Variables were recorded using running recursive sums of 30 s of data printed every 10 s. 15 Gas exchange variables analyzed were V o 2 (mL/kg/min and L/min, standard temperature and pressure, dry), CO 2 production (L/min, standard temperature and pressure, dry), minute ventilation (V e [L/min, body temperature and pressure, saturated]), oxygen pulse (V o 2 divided by heart rate), and respiratory exchange ratio (CO 2 output [V co 2 ] divided by V o 2 ). The ventilatory threshold was determined using plots of the ventilatory equivalents for O 2 and CO 2 and the V-slope method by two independent, blinded (to study phase and the other observer) observers, as outlined previously. 16 
Cardiac Output
Cardiac output was determined during submaximal exercise using a CO 2 rebreathing technique developed by Defares 17 and described in detail elsewhere. 18 Briefly, this technique is based on the application of CO 2 , rather than O 2 , to the Fick equation:
where V co 2 is the volume of CO 2 produced and a-V co 2 difference is the difference in the CO 2 content between the arterial and venous blood. Arterial CO 2 content is estimated from end-tidal Pco 2 from gas exchange. Venous CO 2 content is determined by rebreathing a CO 2 gas mixture and estimating an equilibrium point between the CO 2 content of the lung and the venous blood. Software developed by Medical Graphics Corp (St. Paul, MN) was used to make the cardiac output measurements.
After patients had rested for approximately 30 min following the maximal test, a treadmill workload was chosen that represented approximately 50% of the individual's peak Vo 2 on the baseline test. After a warm-up period, patients were taken to their respective 50% workloads until a constant (steady-state) V o 2 was achieved (5 to 7 min). Patients then began rebreathing a 4% CO 2 /35% O 2 gas mixture for a period of 10 to 15 s. An exponential curve for the rise in V co 2 was generated, representing the point at which the CO 2 content of the lung was equal to 
Results
Clinical characteristics of the 12 patients are presented in Table 1 . A 13th patient experienced lightheadedness during betaxolol therapy and was removed from the study. There were otherwise no untoward events during the therapeutic regimens or exercise evaluations.
Resting Data
Heart rate was significantly reduced during betaxolol therapy, both in the supine (92 Ϯ 27 beats/ min for placebo vs 62 Ϯ 12 beats/min for betaxolol; p Ͻ 0.001) and standing (99 Ϯ 23 vs 66 Ϯ 14 beats/ min; p Ͻ 0.001) positions (Table 2) . Systolic BP was reduced only in the supine position during betaxolol therapy.
Ventilatory Threshold
Heart rate at the ventilatory threshold was reduced by 39 beats/min on betaxolol therapy (p Ͻ 0.001), and systolic BP was reduced by 14 mm Hg (p Ͻ 0.01). V o 2 was reduced by 19% (14.1 Ϯ 3.8 vs 11.4 Ϯ 3.1 mL/kg/min; p ϭ 0.09; Fig 1) . The ventilatory threshold occurred at a similar percentage of maximal V o 2 (66 Ϯ 15% with placebo and 65 Ϯ 12% with betaxolol), and no differences were observed for V e, exercise time, or perceived exertion at this point.
Cardiac Output
Cardiac output, estimated during submaximal exercise by CO 2 rebreathing, was reduced by 15% during betaxolol therapy (12.9 Ϯ 2.3 vs 10.9 Ϯ 1.3; p Ͻ 0.05). Given this reduction in cardiac output and a 43-beat/min reduction in heart rate during steadystate submaximal exercise (p Ͻ 0.001), a significant increase in stroke volume was observed during the betaxolol phase (88.0 Ϯ 20.8 mL/beat with placebo vs 105.6 Ϯ 19.4 mL/beat with betaxolol; p Ͻ 0.05). 
Maximal Exercise
All patients reported fatigue, leg fatigue, or shortness of breath end points at maximal exertion. During both phases of the study, patients achieved mean respiratory exchange ratios of approximately 1.10 and perceived exertion levels greater than 19, suggesting that maximal effort was generally achieved. No differences were observed between betaxolol and placebo phases for these variables.
Maximal heart rate was reduced considerably by betaxolol (from 173 Ϯ 22 beats/min with placebo to 116 Ϯ 24 beats/min with betaxolol; p Ͻ 0.001). A 19% reduction in maximal V o 2 was observed with betaxolol (21.8 Ϯ 5.3 vs 17.6 Ϯ 5.1 mL/kg/min; p Ͻ 0.05; Fig 1) , with similar reductions observed for maximal exercise time, V e, and CO 2 production. Maximal oxygen pulse was significantly higher (2.4 mL/beat) after betaxolol therapy (p Ͻ 0.01).
Relation Between Change in Peak VO 2 and Hemodynamic Measurements
Correlation coeficients between the change in peak Vo 2 (placebo minus betaxolol) and hemodynamic responses are presented in Table 3 . The change in peak Vo 2 was not significantly related to resting or maximal heart rates during placebo therapy, or to changes (placebo minus betaxolol) in resting or maximal heart rates, cardiac ouput, heart rate range, or stroke volume.
Discussion

Ventricular Control and Exercise Capacity
Control of the ventricular response has long been the major therapeutic challenge of treating patients with chronic AF. Previous efforts to control the rapid, irregular heart rate at rest and during exercise have met with mixed results. Digoxin, a mainstay of therapy for this condition, generally fails to control the ventricular rate during exercise. 1, 9, 19, 20 Goldman et al, 19 for example, observed that near-toxic levels of digoxin were required before adequate heart rate control was achieved. Results of studies using ␤-blockade therapy have been paradoxical; while adequate heart rate control is generally achieved, exercise capacity is hindered considerably in some studies, but not in others (Table  4) . DiBianco et al 7 and Atwood et al 4 observed reductions in exercise capacity after ␤-blockade therapy on the order of 15 to 20%, which concurs with the findings in the present study.
Presumably, the considerable reduction in maximal heart rate caused by ␤-blockade (25 to 35 beats/min in previous studies), along with its negative inotropic effects, reduces maximal cardiac out- Figure 1 . Oxygen uptake at the ventilatory threshold and maximal exercise during placebo and betaxolol administration. *⌬ ϭ a change in a given variable, placebo minus betaxolol. Heart rate range is the difference between rest and peak exercise heart rate. put and accounts for the reduction in exercise capacity. In studies in which exercise capacity increased after ␤-blockade, increases in stroke volume presumably more than compensated for the reductions in heart rate to maintain cardiac output. In the present study, the use of once-daily betaxolol had a striking effect on the ventricular response to exercise; we observed mean reductions of 39 beats/min (29%) at the ventilatory threshold and 57 beats/min (33%) at maximal exercise. Both an inordinately high heart rate response to exercise (a hallmark of AF) and an inordinately reduced heart rate response (as might occur with ␤-blockade) are undesirable. The typical uncontrolled ventricular response to exercise in AF probably hinders cardiac output by incomplete and irregular ventricular filling that reduces end-diastolic volume. Conversely, reductions in cardiac output during exercise after ␤-blockade have been documented in normal subjects, 21 and have been suggested, although not directly measured, in patients with AF. More than likely, a balance exists at which heart rate is controlled without compromising cardiac output in AF. The differences between the present findings and those of previous studies are likely attributable to the extent to which the ventricular response is controlled in the different populations of patients with AF; factors such as serum digoxin level, concomitant medications, and underlying disease undoubtedly influence the degree of ventricular control. 1, 22, 23 
Effect of ␤-Blockade on Cardiac Output
The determination of cardiac output by submaximal CO 2 rebreathing is relevant in the context of the present study for several reasons. First, the influence of ␤-blockade therapy on cardiac output at rest and during exercise in patients with AF has not been previously studied. Second, the technique is noninvasive, and although particulars concerning methodology have been argued, numerous studies have validated it. 17, 18, 24 Third, since the technique must be performed submaximally, a steady-state workload can be individualized for a given patient, approximating activities of daily living (mean, 3.0 metabolic equivalents in the present study).
Submaximal cardiac output was reduced by a mean of 2.0 L/min (16%) at this level of exercise after ␤-blockade therapy in the present study, a reduction that was commensurate with the reduction in maximal V o 2 . Submaximal and maximal heart rates were reduced by comparatively greater degrees, suggesting that the compensatory change in stroke volume (which increased by 17.6 mL/beat, or 20%, submaximally) did not adequately compensate for the reduction in heart rate. Interestingly, a trend was observed for an increase in perceived effort at the ventilatory threshold after ␤-blockade therapy (p ϭ 0.11), which confirms our previous observations. 4, 25 These untoward effects of ␤-blockade on cardiac performance, V o 2 , and perceived effort submaximally would appear to be important considerations for patients with AF who continue to work or prefer an active lifestyle.
Effect of ␤-Blockade on Individual Patients
The effect of betaxolol on maximal V o 2 varied considerably; most patients demonstrated reductions, whereas several did not change appreciably. We speculated that patients who had the least ventricular control initially would benefit the most from ␤-blockade (ie, they would most need a strong negative chronotrope). When we evaluated the relationship between maximal heart rate on placebo vs the change in maximal V o 2 (placebo minus betaxolol), we found only a modest association (Table 3) . Likewise, the relationships between the changes in peak Vo 2 and maximal heart rate, submaximal stroke volume, and the heart rate range (maximum minus rest) were only modest (r ϭ 0.21 to 0.55). Thus, while betaxolol clearly reduced heart rate and cardiac output during exercise, and therefore reduced peak V o 2 , there was considerable variation among patients. Establishing which patients might benefit from ␤-blockade therapy on the basis of resting or exercise heart rates remains a difficult undertaking.
Summary
Once-daily betaxolol therapy in patients with chronic AF resulted in significant reductions in the ventricular rate at rest and during exercise. Maximal V o 2 was significantly reduced, but there was considerable variation among patients. Submaximally, stroke volume increased as a compensatory mechanism for the reduction in heart rate, but it is doubtful that the increase in stroke volume was adequate to maintain cardiac output at higher levels of exercise in most patients. Patients with AF who have a relatively controlled ventricular response may benefit from alternative therapies such as calcium-channel blockers, which have been shown to have significant although more modest effects on heart rate during exercise, and do not attenuate maximal V o 2 . 25 
